954149-59-8

Basic information

• Product Name: C₁₉H₁₉N₃O₅
• Synonyms: C₁₉H₁₉N₃O₅
• CAS NO: 954149-59-8
• Molecular Weight: 369.377
• Mol File: 954149-59-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₁₉H₁₉N₃O₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₉H₁₉N₃O₅(954149-59-8)
• EPA Substance Registry System: C₁₉H₁₉N₃O₅(954149-59-8)

Safety Data

• Hazardous Substances Data: 954149-59-8(Hazardous Substances Data)

Upstream product

• 917911-43-4 C₂₁H₂₃N₃O₅ 
• 97483-77-7 2-Cyano-5-bromopyridine 
• 32980-27-1 1-Ethyl 4-hydrogen 2-methylbutanedioate 
• 53399-81-8 ethyl 2-methyl-4-pentenoate 
• 917910-76-0 4-(4-methoxybenzyloxy)-2-hydroxyamidinylpyridine 
• 137067-89-1 ethyl 4-chloro-2-methyl-4-oxobutanoate 
• 917910-75-9 5-[(4-methoxyphenyl)methoxy]pyridine-2-carbonitrile 

Relevant articles and documents

Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): A potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate

Biaryl cyclohexene carboxylic acids were discovered as full and potent niacin receptor (GPR 109A) agonists. Compound 1e (MK-6892) displayed excellent receptor activity, good PK across species, remarkably clean off-target profiles, good ancillary pharmacology, and superior therapeutic window over niacin regarding the FFA reduction versus vasodilation in rats and dogs.

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.